N-acetyl-L-leucine normalizes Transcription Factor EB activity by stereospecific bidirectional modulation in a HeLa cell model of Niemann-Pick disease type C
Lianne C Davis, Wim Annaert, Rebecca Braine, Grant C Churchill, Mallory Factor, Taylor Fields, Marc Patterson, Frances Platt · 2026
Read N-acetyl-L-leucine normalizes Transcription Factor EB activity by stereospecific bidirectional modulation in a HeLa cell model of Niemann-Pick disease type C by Lianne C Davis, Wim Annaert, Rebecca Braine, Grant C Churchill, Mallory Factor, Taylor Fields, Marc Patterson, Frances Platt (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0353834.txt.
Description
Lianne Davis and seven colleagues probe how an approved drug for a rare childhood disease actually works inside cells, in this 2026 PLOS ONE study. Niemann-Pick disease type C jams the cell's recycling centres, the lysosomes. The drug, an altered amino acid, is the only approved single therapy. Working in human cells, including a disease model, the team watched its effect on TFEB, the master switch for lysosome genes.
In healthy cells the drug switched TFEB on; in diseased cells, where the switch was stuck on from stress, it dialled the switch back toward normal. Only one mirror-image form of the molecule worked — the other cancelled it out. The two-way normalising action may explain the drug's benefit.
Catalog record
| CREATOR | Lianne C Davis, Wim Annaert, Rebecca Braine, Grant C Churchill, Mallory Factor, Taylor Fields, Marc Patterson, Frances Platt |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36629 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |